For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a ...

Scientists have discovered a naturally-occurring molecule that aids appetite control and weight loss so well, it may compete with popular GLP-1 agonists like Ozempic.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory ...

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...